CRDL
Cardiol Therapeutics Inc.BS score 12.8LOWPHASE3 · mkt cap $154.1M · rev ttm $0
drug hypothesis
CardiolRx modulates Not disclosed in available trial data to treat Acute Myocarditis.
moa:Not disclosed in available trial data - likely a therapeutic intervention for acute myocarditis targeting myocardial recovery
score breakdown
trial design0
base rate disconnect2
language red flags60
composite12.8
valuation analysis
market cap$154.1M
revenue ttm$0
phasePHASE3
historical base rate40%
disconnect ratio0.1x
lead trialNCT04615949
meta
cik0001702123
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 2 randomized, quadruple-blind, placebo-controlled trial enrolling 109 patients with acute myocarditis. Secondary endpoint includes left-ventricular ejection fraction (LVEF).
primary endpoint:Extracellular volume (ECV) at 12 weeks post randomization
claimed differentiation
Not disclosed in available trial data
language red flags
- Very limited public information available - target, mechanism of action, and differentiation claims not disclosed in this clinical trial registry data
- Unable to assess hedging or promotional language as only clinical trial metadata was provided
- Data appears to be from ClinicalTrials.gov registry rather than SEC filing - limited corporate disclosures available
company-stated risks
- Not disclosed in available trial data
upcoming catalysts
- 2025-01-31Primary trial completion